Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cytrx Corp (CYTR)

Cytrx Corp (CYTR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 5,440
  • Shares Outstanding, K 43,483
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,180 K
  • 60-Month Beta 2.18
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.93
Trade CYTR with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.11
  • Most Recent Earnings -0.04 on 05/12/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 0.249 on 03/07/08
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0940 +27.87%
on 05/13/22
0.1659 -27.55%
on 04/28/22
-0.0297 (-19.81%)
since 04/22/22
3-Month
0.0940 +27.87%
on 05/13/22
0.5000 -75.96%
on 02/25/22
-0.3398 (-73.87%)
since 02/24/22
52-Week
0.0940 +27.87%
on 05/13/22
4.7000 -97.44%
on 06/10/21
-1.5998 (-93.01%)
since 05/24/21

Most Recent Stories

More News
CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that its Board...

CYTR : 0.1202 (-3.92%)
CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic...

CYTR : 0.1202 (-3.92%)
CytRx Partners with Oncology Development Expert to Advance LADR Platform

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has partnered...

CYTR : 0.1202 (-3.92%)
CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below letter to...

CYTR : 0.1202 (-3.92%)
CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented...

ORPH : 0.8700 (-2.25%)
CYTR : 0.1202 (-3.92%)
CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted...

ORPH : 0.8700 (-2.25%)
CYTR : 0.1202 (-3.92%)
CytRx to Hold Town Hall for Stockholders on Thursday, January 20th

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories,...

CYTR : 0.1202 (-3.92%)
CytRx to Participate in the H.C. Wainwright BioConnect Virtual Conference

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories,...

CYTR : 0.1202 (-3.92%)
CytRx Announces the Appointment of Dr. Stephen Snowdy as Chief Executive Officer

CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development in oncology and neurodegenerative diseases, today announced...

VTI : 196.67 (-1.00%)
CYTR : 0.1202 (-3.92%)
CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Ongoing Clinical Studies for Various Forms of Cancer

CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development in oncology and neurodegenerative diseases, today highlighted...

IBRX : 3.68 (-3.41%)
CYTR : 0.1202 (-3.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.1535
2nd Resistance Point 0.1469
1st Resistance Point 0.1335
Last Price 0.1202
1st Support Level 0.1135
2nd Support Level 0.1069
3rd Support Level 0.0935

See More

52-Week High 4.7000
Fibonacci 61.8% 2.9405
Fibonacci 50% 2.3970
Fibonacci 38.2% 1.8535
Last Price 0.1202
52-Week Low 0.0940

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar